covid novavax - Search News

Order byBest matchMost fresh

COVID-19 vaccine, FDA and Novavax

Top News

Overview

Impacts

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

The Food and Drug Administration gave Covid vaccine manufacturers instructions on what next fall’s Covid vaccines should target on Thursday, signaling it would prefer that they update the strain in t...

STAT · 5h

· 5d · on MSN

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk

· 4d · on MSN

Novavax Stock Soars on FDA Approval for New COVID-19 Vaccine

The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.

Covid vaccines will soon be required to go through more rigorous trials to ensure that they really are beneficial for people who aren’t at high risk.

MIT Technology Review · 12h

· 7h

Here's what to know about the FDA's COVID-19 vaccine changes

· 1d

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 1d

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

· 1d

COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say

Medical Marketing & Media1d

FDA to limit COVID boosters, Trump touts ‘Most Favored Nation’ framework

Additionally, the Department of Health and Human Services unveiled the framework for the Most Favored Nation drug pricing plan announced last week by President Donald Trump.

10hon MSN

FDA advisers recommend updating COVID shots to JN.1 strain

Moderna (MRNA), and Novavax (NVAX) agree as the FDA advisors recommend targeting JN.1 strain for updated COVID vaccines this fall. Read more here.

FDA Sets New COVID Booster Guidelines Requiring Trials for Approvals for Healthy Adults

FDA Commissioner Marty Makary and top U.S. vaccines regulator Vinay Prasad said based on data from tests that measure immune response in patients, they anticipate that the FDA will be able to approve the boosters for adults over the age of 65 years.